Alvotech reported key events since its Q1 2025 earnings on May 7, including management changes, acquisitions, and a successful financing round, with gross proceeds from a recent share placement totaling approximately SEK 750 million. Notably, on July 10, 2025, Linda Jonsdottir was appointed CFO, replacing Joel Morales, and the company entered into significant agreements to expand its biosimilar product offerings, including a partnership with Advanz Pharma worth up to EUR 160 million.